Protagonist Therapeutics Inc
NASDAQ:PTGX 3:58:50 PM EDT
| Market Cap (Intraday) | 1.15B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $26.37 |
| 50-Day MA | $27.17 |
| 200-Day MA | $22.10 |
Protagonist Therapeutics, Inc. Stock, NASDAQ:PTGX
7707 Gateway Boulevard, Suite 140, Newark, California 94560-1160
Phone: +1.510.474.0170
Number of Employees: 73
Description
Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.